Cargando…
Discovery of a Novel Class of Dual GPBAR1 Agonists–RORγt Inverse Agonists for the Treatment of IL-17-Mediated Disorders
[Image: see text] Retinoic acid receptor-related orphan receptor γ-t (RORγt) and GPBAR1, a transmembrane G-protein-coupled receptor for bile acids, are attractive drug targets to develop clinically relevant small modulators as potent therapeutics for autoimmune diseases. Herein, we designed, synthes...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Chemical Society
2023
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9933477/ https://www.ncbi.nlm.nih.gov/pubmed/36816679 http://dx.doi.org/10.1021/acsomega.2c07907 |
_version_ | 1784889686382084096 |
---|---|
author | Fiorillo, Bianca Roselli, Rosalinda Finamore, Claudia Biagioli, Michele di Giorgio, Cristina Bordoni, Martina Conflitti, Paolo Marchianò, Silvia Bellini, Rachele Rapacciuolo, Pasquale Cassiano, Chiara Limongelli, Vittorio Sepe, Valentina Catalanotti, Bruno Fiorucci, Stefano Zampella, Angela |
author_facet | Fiorillo, Bianca Roselli, Rosalinda Finamore, Claudia Biagioli, Michele di Giorgio, Cristina Bordoni, Martina Conflitti, Paolo Marchianò, Silvia Bellini, Rachele Rapacciuolo, Pasquale Cassiano, Chiara Limongelli, Vittorio Sepe, Valentina Catalanotti, Bruno Fiorucci, Stefano Zampella, Angela |
author_sort | Fiorillo, Bianca |
collection | PubMed |
description | [Image: see text] Retinoic acid receptor-related orphan receptor γ-t (RORγt) and GPBAR1, a transmembrane G-protein-coupled receptor for bile acids, are attractive drug targets to develop clinically relevant small modulators as potent therapeutics for autoimmune diseases. Herein, we designed, synthesized, and evaluated several new bile acid-derived ligands with potent dual activity. Furthermore, we performed molecular docking and MD calculations of the best dual modulators in the two targets to identify the binding modes as well as to better understand the molecular basis of the inverse agonism of RORγt by bile acid derivatives. Among these compounds, 7 was identified as a GPBAR1 agonist (EC(50) 5.9 μM) and RORγt inverse agonist (IC(50) 0.107 μM), with excellent pharmacokinetic properties. Finally, the most promising ligand displayed robust anti-inflammatory activity in vitro and in vivo in a mouse model of 2,4,6-trinitrobenzene sulfonic acid (TNBS)-induced colitis. |
format | Online Article Text |
id | pubmed-9933477 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | American Chemical Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-99334772023-02-17 Discovery of a Novel Class of Dual GPBAR1 Agonists–RORγt Inverse Agonists for the Treatment of IL-17-Mediated Disorders Fiorillo, Bianca Roselli, Rosalinda Finamore, Claudia Biagioli, Michele di Giorgio, Cristina Bordoni, Martina Conflitti, Paolo Marchianò, Silvia Bellini, Rachele Rapacciuolo, Pasquale Cassiano, Chiara Limongelli, Vittorio Sepe, Valentina Catalanotti, Bruno Fiorucci, Stefano Zampella, Angela ACS Omega [Image: see text] Retinoic acid receptor-related orphan receptor γ-t (RORγt) and GPBAR1, a transmembrane G-protein-coupled receptor for bile acids, are attractive drug targets to develop clinically relevant small modulators as potent therapeutics for autoimmune diseases. Herein, we designed, synthesized, and evaluated several new bile acid-derived ligands with potent dual activity. Furthermore, we performed molecular docking and MD calculations of the best dual modulators in the two targets to identify the binding modes as well as to better understand the molecular basis of the inverse agonism of RORγt by bile acid derivatives. Among these compounds, 7 was identified as a GPBAR1 agonist (EC(50) 5.9 μM) and RORγt inverse agonist (IC(50) 0.107 μM), with excellent pharmacokinetic properties. Finally, the most promising ligand displayed robust anti-inflammatory activity in vitro and in vivo in a mouse model of 2,4,6-trinitrobenzene sulfonic acid (TNBS)-induced colitis. American Chemical Society 2023-01-31 /pmc/articles/PMC9933477/ /pubmed/36816679 http://dx.doi.org/10.1021/acsomega.2c07907 Text en © 2023 The Authors. Published by American Chemical Society https://creativecommons.org/licenses/by-nc-nd/4.0/Permits non-commercial access and re-use, provided that author attribution and integrity are maintained; but does not permit creation of adaptations or other derivative works (https://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Fiorillo, Bianca Roselli, Rosalinda Finamore, Claudia Biagioli, Michele di Giorgio, Cristina Bordoni, Martina Conflitti, Paolo Marchianò, Silvia Bellini, Rachele Rapacciuolo, Pasquale Cassiano, Chiara Limongelli, Vittorio Sepe, Valentina Catalanotti, Bruno Fiorucci, Stefano Zampella, Angela Discovery of a Novel Class of Dual GPBAR1 Agonists–RORγt Inverse Agonists for the Treatment of IL-17-Mediated Disorders |
title | Discovery of a
Novel Class of Dual GPBAR1 Agonists–RORγt
Inverse Agonists for the Treatment of IL-17-Mediated Disorders |
title_full | Discovery of a
Novel Class of Dual GPBAR1 Agonists–RORγt
Inverse Agonists for the Treatment of IL-17-Mediated Disorders |
title_fullStr | Discovery of a
Novel Class of Dual GPBAR1 Agonists–RORγt
Inverse Agonists for the Treatment of IL-17-Mediated Disorders |
title_full_unstemmed | Discovery of a
Novel Class of Dual GPBAR1 Agonists–RORγt
Inverse Agonists for the Treatment of IL-17-Mediated Disorders |
title_short | Discovery of a
Novel Class of Dual GPBAR1 Agonists–RORγt
Inverse Agonists for the Treatment of IL-17-Mediated Disorders |
title_sort | discovery of a
novel class of dual gpbar1 agonists–rorγt
inverse agonists for the treatment of il-17-mediated disorders |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9933477/ https://www.ncbi.nlm.nih.gov/pubmed/36816679 http://dx.doi.org/10.1021/acsomega.2c07907 |
work_keys_str_mv | AT fiorillobianca discoveryofanovelclassofdualgpbar1agonistsrorgtinverseagonistsforthetreatmentofil17mediateddisorders AT rosellirosalinda discoveryofanovelclassofdualgpbar1agonistsrorgtinverseagonistsforthetreatmentofil17mediateddisorders AT finamoreclaudia discoveryofanovelclassofdualgpbar1agonistsrorgtinverseagonistsforthetreatmentofil17mediateddisorders AT biagiolimichele discoveryofanovelclassofdualgpbar1agonistsrorgtinverseagonistsforthetreatmentofil17mediateddisorders AT digiorgiocristina discoveryofanovelclassofdualgpbar1agonistsrorgtinverseagonistsforthetreatmentofil17mediateddisorders AT bordonimartina discoveryofanovelclassofdualgpbar1agonistsrorgtinverseagonistsforthetreatmentofil17mediateddisorders AT conflittipaolo discoveryofanovelclassofdualgpbar1agonistsrorgtinverseagonistsforthetreatmentofil17mediateddisorders AT marchianosilvia discoveryofanovelclassofdualgpbar1agonistsrorgtinverseagonistsforthetreatmentofil17mediateddisorders AT bellinirachele discoveryofanovelclassofdualgpbar1agonistsrorgtinverseagonistsforthetreatmentofil17mediateddisorders AT rapacciuolopasquale discoveryofanovelclassofdualgpbar1agonistsrorgtinverseagonistsforthetreatmentofil17mediateddisorders AT cassianochiara discoveryofanovelclassofdualgpbar1agonistsrorgtinverseagonistsforthetreatmentofil17mediateddisorders AT limongellivittorio discoveryofanovelclassofdualgpbar1agonistsrorgtinverseagonistsforthetreatmentofil17mediateddisorders AT sepevalentina discoveryofanovelclassofdualgpbar1agonistsrorgtinverseagonistsforthetreatmentofil17mediateddisorders AT catalanottibruno discoveryofanovelclassofdualgpbar1agonistsrorgtinverseagonistsforthetreatmentofil17mediateddisorders AT fioruccistefano discoveryofanovelclassofdualgpbar1agonistsrorgtinverseagonistsforthetreatmentofil17mediateddisorders AT zampellaangela discoveryofanovelclassofdualgpbar1agonistsrorgtinverseagonistsforthetreatmentofil17mediateddisorders |